Patients undergoing allogeneic stem-cell transplantation (allo-SCT) have reduced responses to vaccines due to immunosuppressive status linked to GvHD prophylaxis and treatment. In our study, we compared humoral responses to anti-SARS-CoV-2 mRNA vaccine, and infection onset, according to patients and transplant features; we also evaluated cellular response in patients without seroconversion.

Methods

We tested antibodies titer after second and third vaccine doses. Antibodies were detected through an immune-enzymatic assay. In a patients’ subgroup without seroconversion, we tested cell-mediated responses evaluating interferon-gamma release by T-lymphocytes exposed to virus spike protein.

Results

Seroconversion rate increased from 66% at 30 days to 81% at 90 days after the second dose; it was 97% at 150 days after the third dose. We found a significant association between seroconversion after the second dose and two variables: shorter interval between allo-SCT and vaccination; ongoing immunosuppression. Twelve of 19 patients (63%) without antibodies after the second dose did not show cellular responses. Nineteen percent of patients developed SARS-CoV-2 infection after the third dose, with favorable outcome in all cases. Patients within 12 months after allo-SCT showed a significantly higher infection risk.

Conclusions

Our study suggests that an interval shorter than 12 months between allo-SCT and first vaccine dose and/or ongoing immunosuppression were associated with humoral and cellular response deficiency after two doses. Third dose induced an increased and sustained humoral response in the majority of patients. However, patients within 1 year after allo-SCT remained at higher infection risk and may be candidate for prophylaxis with anti-SARS-CoV-2 monoclonal antibodies.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Open Research

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supporting Information

REFERENCES

1Pagano L, Salmanton-García J, Marchesi F, et al. EPICOVIDEHA working group. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021; 14(1): 168.
10.1186/s13045-021-01177-0
CAS PubMed Web of Science® Google Scholar
2Passamonti F, Cattaneo C, Arcaini L, et al. ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020; 7(10): e737-e745.
10.1016/S2352-3026(20)30251-9
PubMed Web of Science® Google Scholar
3Palanques-Pastor T, Megías-Vericat JE, Martínez P, et al. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leuk Lymphoma. 2021; 62(12): 2928-2938.
10.1080/10428194.2021.1948031
CAS PubMed Web of Science® Google Scholar
4Negahdaripour M, Shafiekhani M, Moezzi SMI, et al. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol. 2021; 99:108021.
10.1016/j.intimp.2021.108021
CAS PubMed Web of Science® Google Scholar
5Sharma A, Bhatt N, St Martin A et al., Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021; 8(3): e185-e193.
10.1016/S2352-3026(20)30429-4
CAS PubMed Web of Science® Google Scholar
6Clémenceau B, Guillaume T, Coste-Burel M, et al. SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine. Vaccines (Basel). 2022; 10(3): 448.
10.3390/vaccines10030448
CAS PubMed Web of Science® Google Scholar
7Ram R, Hagin D, Kikozashvilli N, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy—a single-center prospective cohort study. Transplant Cell Ther. 2021; 27(9): 788-794.
10.1016/j.jtct.2021.06.024
CAS PubMed Google Scholar
8Redjoul R, Le Bouter A, Parinet V, et al. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol. 2021; 8(10): e681-e683.
10.1016/S2352-3026(21)00274-X
CAS PubMed Web of Science® Google Scholar
9Einarsdottir S, Martner A, Waldenström J, et al. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Adv. 2022; 10;6(9): 2723-2730.
10.1182/bloodadvances.2021006937
Google Scholar
10Kimura Y, Hirabayashi E, Yano M, et al. COVID-19 Omicron variant-induced laryngitis. Auris Nasus Larynx. 2022:S0385-8146(22)00200-0. doi:10.1016/j.anl.2022.08.007
10.1016/j.anl.2022.08.007
Web of Science® Google Scholar

Citing Literature

Volume25, Issue2

April 2023

e14003